Literature DB >> 25748742

Multiple primary malignancies in patients with non-small cell lung cancer.

Shiro Fujita1, Katsuhiro Masago, Jumpei Takeshita, Yosuke Togashi, Akito Hata, Reiko Kaji, Masaki Kokubo, Nobuyuki Katakami.   

Abstract

OBJECTIVE: Information regarding multiple primary malignancies is important, as it has the potential to clarify etiological factors and may indicate the need to refine patient follow-up to include screening for associated malignancies. Upper aerodigestive tract cancer often develops in patients with smoking-related lung cancer; however, little is known about the frequencies or types of other primary malignancies in patients with non-small cell lung cancer (NSCLC) without a history of smoking.
METHODS: We retrospectively evaluated the records of patients examined and/or treated for NSCLC at the Institute of Biomedical Research and Innovation between January 2007 and June 2012. Patients In total, 938 patients, including 599 men (never-smoker/ever-smoker: 35/564) and 339 women (never-smoker/ever-smoker: 236/103), were analyzed.
RESULTS: Among the 209 patients (22.3%) with multiple primary malignancies, 151 had a history of smoking and 58 were never-smokers. The most common cancers were gastric (43 cases), colorectal (33 cases), and prostate (29 cases) cancer. Smoking-related cancer was more common in current smokers and ex-smokers for both men and women. Among women with NSCLC, never-smokers were more likely to have thyroid cancer than those with a history of smoking (5.1% vs. 0%, p=0.021).
CONCLUSION: In this study, several differences in malignancies were observed between never-smokers and patients with a history of smoking. Thyroid cancer and NSCLC co-existed in some women without a history of smoking, implicating predisposing factors other than tobacco smoke in the onset of these cancers.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25748742     DOI: 10.2169/internalmedicine.54.2921

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  9 in total

1.  Impact of multiple malignancies on surgical outcomes in patients with 1 cm or smaller non-small cell lung cancer.

Authors:  Takuma Tsukioka; Nobuhiro Izumi; Shinjiro Mizuguchi; Chung Kyukwang; Hiroaki Komatsu; Michihito Toda; Kantaro Hara; Hikaru Miyamoto; Noritoshi Nishiyama
Journal:  Int J Clin Oncol       Date:  2017-09-01       Impact factor: 3.402

2.  Phenotype-genotype correlation in multiple primary lung cancer patients in China.

Authors:  Yang Yang; Wei Yin; Wenxin He; Chao Jiang; Xiao Zhou; Xiao Song; Junjie Zhu; Ke Fei; Weijun Cao; Gening Jiang
Journal:  Sci Rep       Date:  2016-10-31       Impact factor: 4.379

3.  Meta-Analysis and Systematic Review in Environmental Tobacco Smoke Risk of Female Lung Cancer by Research Type.

Authors:  Xue Ni; Ning Xu; Qiang Wang
Journal:  Int J Environ Res Public Health       Date:  2018-06-27       Impact factor: 3.390

4.  Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine.

Authors:  Norimichi Akiyama; Masato Karayama; Moriya Iwaizumi; Yukiko Kusama; Masato Kono; Hironao Hozumi; Yuzo Suzuki; Kazuki Furuhashi; Noriyuki Enomoto; Tomoyuki Fujisawa; Yutaro Nakamura; Naoki Inui; Takafumi Suda
Journal:  Intern Med       Date:  2017-08-10       Impact factor: 1.271

5.  Alteration of DNA mismatch repair capacity underlying the co-occurrence of non-small-cell lung cancer and nonmedullary thyroid cancer.

Authors:  Shiro Fujita; Katsuhiro Masago
Journal:  Sci Rep       Date:  2021-02-11       Impact factor: 4.379

6.  Genetic Analysis and Targeted Therapy Using Buparlisib and MK2206 in a Patient with Triple Metachronous Cancers of the Kidney, Prostate, and Squamous Cell Carcinoma of the Lung: A Case Report.

Authors:  Tong Zhao; Yuqin Tian; Xinjia Ding; Lin Liu; Bowen Tan; Bin Yang; Jianlin Wu; Ting Lei; Ruoyu Wang; Yan Ding
Journal:  Onco Targets Ther       Date:  2021-04-28       Impact factor: 4.147

7.  Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers.

Authors:  Wen-Ru Chou; Ben-Chang Shia; Yen-Chun Huang; Chieh-Wen Ho; Mingchih Chen
Journal:  J Clin Med       Date:  2022-09-04       Impact factor: 4.964

8.  Survival Analysis in Patients with Lung Cancer and Subsequent Primary Cancer: A Nationwide Cancer Registry Study.

Authors:  Wen-Ru Chou; Ben-Chang Shia; Yen-Chun Huang; Chieh-Wen Ho; Mingchih Chen
Journal:  J Clin Med       Date:  2022-10-08       Impact factor: 4.964

9.  Synchronous Primary Lung Adenocarcinoma and Hepatocellular Carcinoma Successfully Treated with a Combination of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel.

Authors:  Takashi Egawa; Keita Masuzawa; Sohei Nakayama; Ichiro Maeda; Satoshi Tsunematsu; Yukio Suzuki; Yusuke Suzuki
Journal:  Intern Med       Date:  2021-04-12       Impact factor: 1.271

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.